ES3060767T3 - Alginate film comprising a triptan - Google Patents

Alginate film comprising a triptan

Info

Publication number
ES3060767T3
ES3060767T3 ES17804124T ES17804124T ES3060767T3 ES 3060767 T3 ES3060767 T3 ES 3060767T3 ES 17804124 T ES17804124 T ES 17804124T ES 17804124 T ES17804124 T ES 17804124T ES 3060767 T3 ES3060767 T3 ES 3060767T3
Authority
ES
Spain
Prior art keywords
triptan
alginate
film
alginate film
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17804124T
Other languages
English (en)
Spanish (es)
Inventor
Scott Boyer
Fredrik Hübinette
Leif Ingemarsson
Susan Suchdev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Klaria Pharma Holding AB
Original Assignee
Klaria Pharma Holding AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klaria Pharma Holding AB filed Critical Klaria Pharma Holding AB
Application granted granted Critical
Publication of ES3060767T3 publication Critical patent/ES3060767T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacture Of Macromolecular Shaped Articles (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES17804124T 2016-11-15 2017-11-14 Alginate film comprising a triptan Active ES3060767T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201619324 2016-11-15
PCT/EP2017/079217 WO2018091473A1 (en) 2016-11-15 2017-11-14 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
ES3060767T3 true ES3060767T3 (en) 2026-03-30

Family

ID=60452618

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17804124T Active ES3060767T3 (en) 2016-11-15 2017-11-14 Alginate film comprising a triptan

Country Status (15)

Country Link
US (4) US11007144B2 (https=)
EP (2) EP4631569A3 (https=)
JP (2) JP2020500220A (https=)
KR (1) KR102499414B1 (https=)
CN (1) CN110381921A (https=)
AU (1) AU2017359973B2 (https=)
BR (1) BR112019009775A2 (https=)
DK (1) DK3541362T3 (https=)
ES (1) ES3060767T3 (https=)
FI (1) FI3541362T3 (https=)
IL (1) IL266537B2 (https=)
MX (1) MX389336B (https=)
PT (1) PT3541362T (https=)
RU (1) RU2767436C2 (https=)
WO (1) WO2018091473A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX389336B (es) 2016-11-15 2025-03-20 Klaria Pharma Holding Ab Formulacion farmaceutica.
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
GB201808462D0 (en) 2018-05-23 2018-07-11 Klaria Pharma Holding Ab Pharmaceutical formulation
EP3912622A1 (en) 2020-05-19 2021-11-24 tesa Labtec GmbH Oral film for safe administration of api
DE102020122557A1 (de) * 2020-08-28 2022-03-03 Lts Lohmann Therapie-Systeme Ag Mucosa-Perforierung
KR102413426B1 (ko) * 2020-12-21 2022-06-29 주식회사 씨엠지제약 나라트립탄을 포함하는 구강용해 필름 제형
DE102021105268A1 (de) * 2021-03-04 2022-09-08 Lts Lohmann Therapie-Systeme Ag. Oraler Dünnfilm

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB933462A (en) 1958-12-17 1963-08-08 Simone Marie Antoinette Radouc Improvements in or relating to the treatment of meat
US5288498A (en) 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US5785989A (en) 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
AU3693397A (en) 1996-07-10 1998-02-02 Novartis Consumer Health S.A. Oral pharmaceutical combinations of antihistaminic compounds and terpenoids
AU3444297A (en) 1996-07-12 1998-02-09 Novartis Consumer Health S.A. Oral pharmaceutical combinations of nsaids with terpenoids
US6596298B2 (en) 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
KR100452972B1 (ko) 2000-05-16 2004-10-14 주식회사 삼양사 경피투여용 하이드로젤 조성물
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
US20040247649A1 (en) 2002-02-11 2004-12-09 Edizone, Lc Medicine-containing orally soluble films
AU2003240824B9 (en) 2002-05-31 2008-09-25 University Of Mississippi Transmucosal delivery of cannabinoids
DE10226494A1 (de) 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
GB0217382D0 (en) 2002-07-26 2002-09-04 Pfizer Ltd Process for making orally consumable dosage forms
US9561182B2 (en) 2003-08-22 2017-02-07 Cure Pharmaceutical Corporation Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals
US20040096569A1 (en) 2002-11-15 2004-05-20 Barkalow David G. Edible film products and methods of making same
US9498454B2 (en) 2003-02-24 2016-11-22 Pharmaceutical Productions Inc. Transmucosal drug delivery system
CN1777411B (zh) 2003-02-24 2013-01-02 药品生产公司 经粘膜药物递送系统
US20070059346A1 (en) 2003-07-01 2007-03-15 Todd Maibach Film comprising therapeutic agents
KR20050048056A (ko) 2003-11-18 2005-05-24 (주)케이비피 경구용 소모 필름 조성물
US20080254108A1 (en) 2004-08-23 2008-10-16 Mark Rosenberg Formulations and Methods for Modulating Satiety
DK2377557T3 (en) 2004-11-24 2017-02-06 Meda Pharmaceuticals Inc Compositions comprising azelastine and methods for its use
WO2006095267A1 (en) 2005-03-10 2006-09-14 Institut Pasteur Compositions for the treatment of tumour pathologies, comprising internalin b (in1b) of listeria monocytogene protein or a fragment thereof
CA2656966C (en) 2005-03-15 2014-06-10 Animal Ethics Pty Ltd A topical analgesic composition
TW200800142A (en) 2005-09-09 2008-01-01 Univ Manitoba Fast-disintegrating epinephrine tablets for buccal or sublingual administration
GB2423711B (en) 2005-10-24 2007-02-14 Fortune Apex Dev Ltd Method for preparing a pharmaceutical composition with enhanced mucoadhesion
SE530184C2 (sv) * 2005-12-23 2008-03-18 Kjell Stenberg Bioadhesiv farmaceutisk filmkomposition innehållande lågviskösa alginater
IL175338A0 (en) 2006-05-01 2006-09-05 Biota Ltd Orally administrable films and preparation thereof
CN101081218A (zh) 2006-06-02 2007-12-05 范敏华 一种口腔速崩膜及其制备方法
US20070293581A1 (en) 2006-06-05 2007-12-20 Malcolm Hill Methods for Buccal, Lingual or Sublingual Dosing Regimens of Epinephrine for the Treatment of Allergic Emergencies
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
KR100855566B1 (ko) 2006-09-12 2008-09-03 (주) 아모젠 경구용 소모성 필름
DK2074141T3 (en) 2006-09-22 2016-11-28 Novo Nordisk As The protease resistant insulin analogues.
US20080269347A1 (en) 2006-09-28 2008-10-30 Azopharma, Inc. Epinephrine formulations
ES2364865T3 (es) 2006-12-11 2011-09-15 Kempharm, Inc. Conjugados de ornitina de la anfetamina y procedimientos de fabricación y de utilización de los mismos.
MX2009008030A (es) 2007-01-31 2009-10-19 Univ Rutgers Liberacion controlada de activos en la piel.
WO2008098195A2 (en) 2007-02-09 2008-08-14 Todd Maibach Film comprising nitroglycerin
US8420112B2 (en) * 2008-03-21 2013-04-16 Paindure Ltd. Solid dosage form for treating headaches
US20090246273A1 (en) 2008-03-27 2009-10-01 Al-Ghananeem Abeer M Ketorolac Sublingual Spray for the Treatment of Pain
WO2009126132A1 (en) 2008-03-31 2009-10-15 Mark Rosenberg Formulations and methods for modulating satiety
JP6002385B2 (ja) 2008-09-12 2016-10-05 クリティカル ファーマシューティカルズ リミテッドＣｒｉｔｉｃａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｉｍｉｔｅｄ 医薬組成物、医薬組成物における吸収促進剤の使用方法、及び医薬組成物の製造方法
US8715715B2 (en) * 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
US8900634B2 (en) 2008-11-03 2014-12-02 Nal Pharmaceuticals, Ltd. Diethylstilbestrol dosage form and methods of treatment using thereof
CN101574330A (zh) 2009-06-12 2009-11-11 上海现代药物制剂工程研究中心有限公司 苯甲酸利扎曲普坦膜剂
KR101074271B1 (ko) 2009-06-25 2011-10-17 (주)차바이오앤디오스텍 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
CA2775404C (en) * 2009-09-25 2017-01-03 Dr. Reddy's Laboratories Limited Formulations comprising triptan compounds
DK3254676T3 (en) 2009-10-30 2019-03-11 Ix Biopharma Ltd QUICK-SOLVING SOLID DOSAGE FORM
KR101077468B1 (ko) 2011-03-04 2011-11-07 (주)차바이오앤디오스텍 안정한 경구용 속용 필름 제제
KR101303479B1 (ko) 2011-07-28 2013-09-06 (주)씨엘팜 가식성 필름형성 조성물 및 약물이 함유된 가식성 필름형 제제
WO2013019187A1 (en) 2011-07-29 2013-02-07 Kempharm, Inc. Homoarginine prodrugs and/or conjugates of amphetamine and other stimulants and processes for making and using the same
WO2013052770A1 (en) 2011-10-05 2013-04-11 Sanders Jennifer L Methods and compositions for treating foot or hand pain
CA2853084C (en) 2011-10-21 2022-04-26 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
UA116440C2 (uk) 2012-03-27 2018-03-26 Нікоссіно Аб Композиція нікотину
WO2013171146A1 (en) 2012-05-15 2013-11-21 Lts Lohmann Therapie-Systeme Ag Oral film containing enteric release opiate resinate
US9789071B2 (en) 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
US10568831B2 (en) 2012-06-29 2020-02-25 Wisconsin Alumni Research Foundation Method to enhance swallowing safety and appeal of beverages for treating dysphagia based on rheological and sensory parameters
FR2994844B1 (fr) 2012-08-31 2015-01-02 Assist Publ Hopitaux De Paris Formulation gelifiante a base de ketamine
CN102871984B (zh) 2012-11-05 2015-11-11 天津市聚星康华医药科技有限公司 一种盐酸去氧肾上腺素口腔速溶膜及其制备方法
CN102961365B (zh) 2012-12-17 2016-01-20 天津市聚星康华医药科技有限公司 硫酸特布他林口腔速溶膜及其制备方法
WO2014137189A1 (ko) 2013-03-07 2014-09-12 에스케이케미칼주식회사 고함량의 약물을 함유하는 구강 붕해 필름 및 이의 제조방법
WO2014160404A1 (en) 2013-03-13 2014-10-02 The Regents Of The University Of California Improved oral drug devices and drug formulations
JP2016521759A (ja) 2013-06-17 2016-07-25 リグスホスピタルＲｉｇｓｈｏｓｐｉｔａｌｅｔ アドレナリンおよびクエン酸を含む注射用医薬組成物
DE202013105715U1 (de) 2013-08-22 2014-02-19 Sipnose Ltd. Vorrichtung zur Abgabe einer vorbestimmten Menge einer Substanz an eine natürliche Öffnung des Körpers
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
WO2015074663A1 (en) 2013-11-19 2015-05-28 Rigshospitalet Injectable pharmaceutical compositions comprising iloprost
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
MX377377B (es) 2014-04-15 2025-03-10 Propella Therapeutics Inc Composiciones tópicas para el alivio del dolor, manufactura y uso.
US9044390B1 (en) 2014-04-17 2015-06-02 Gary J. Speier Pharmaceutical composition and method of manufacturing
WO2015195708A1 (en) 2014-06-16 2015-12-23 Loewi LLC Methods of anesthetizing nerve tissue in the trigeminal nerve pathway and medical uses thereof
US10307397B2 (en) 2014-07-28 2019-06-04 Concept Matrix Solutions Oral dissolvable film that includes plant extract
WO2016015798A1 (en) 2014-07-31 2016-02-04 Pharmathen S.A. Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population
US10383950B2 (en) 2014-08-14 2019-08-20 Helmholtz-Zentrum Fur Infektionsforschung Gmbh (De/De) Methods and compositions of carrier systems for the purpose of intracellular drug targeting
CN105878171A (zh) 2014-12-22 2016-08-24 南京海恒医药科技有限公司 一种依达拉奉新制剂及其制备方法
WO2016161537A1 (en) 2015-04-08 2016-10-13 Maxinase Life Sciences Limited Bioadhesive compositions for intranasal administration of granistron
US10064816B2 (en) 2015-06-11 2018-09-04 ReJoy Treatment of sexual dysfunction
US11191734B2 (en) 2015-06-27 2021-12-07 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
WO2017020125A1 (en) 2015-07-31 2017-02-09 Delivra Inc. Transdermal formulations for delivery of capsaicinoids
WO2017030555A1 (en) 2015-08-17 2017-02-23 Bhalani Vinayak T Topical film delivery system
US10039710B2 (en) 2015-09-18 2018-08-07 Insys Development Company, Inc. Epinephrine spray formulations
US20170079907A1 (en) 2015-09-18 2017-03-23 Insys Development Company, Inc. Sublingual Epinephrine Spray
US9833461B2 (en) 2015-10-23 2017-12-05 Ctt Pharma Inc. Therapeutic compositions comprising cannabidiol and corticosteroids
ES2949053T3 (es) 2016-01-07 2023-09-25 Viramal Ltd Composiciones de gel para administración transdérmica para maximizar las concentraciones de fármaco en el estrato córneo y suero, y métodos de uso de las mismas
WO2017132410A1 (en) 2016-01-26 2017-08-03 Frank Litvack Compositions and uses of alpha-adrenergic agents
WO2017135195A1 (ja) 2016-02-03 2017-08-10 社会医療法人蘇西厚生会 まつなみリサーチパーク アレルギー症状の予防又は治療剤
US10265362B2 (en) 2016-04-12 2019-04-23 Scott Schaneville Ingestible films having substances from hemp or cannabis
KR20230137362A (ko) 2016-05-05 2023-10-04 어퀘스티브 테라퓨틱스, 아이엔씨. 강화된 전달 에프네프린 조성물
WO2017192923A1 (en) 2016-05-05 2017-11-09 Monosol Rx, Llc Pharmaceutical compositions with enhanced permeation
US20180125977A1 (en) 2016-05-05 2018-05-10 Monosol Rx, Llc Enhanced delivery epinephrine compositions
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US20190350881A1 (en) 2016-06-17 2019-11-21 Ys Pharmtech Stabilization of epinephrine formulations
MX389336B (es) 2016-11-15 2025-03-20 Klaria Pharma Holding Ab Formulacion farmaceutica.
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
GB201807942D0 (en) 2018-05-16 2018-06-27 Klaria Pharma Holding Ab Pharmaceutical formulation
GB201808462D0 (en) 2018-05-23 2018-07-11 Klaria Pharma Holding Ab Pharmaceutical formulation
GB201911715D0 (en) 2019-08-15 2019-10-02 Klaria Pharma Holding Ab Film formulation comprising carriers
GB201912505D0 (en) 2019-08-30 2019-10-16 Klaria Pharma Holding Ab Pharmaceutical formulation
EP4054523B1 (en) 2019-11-04 2025-08-06 Biota Ltd. Orally administrable films comprising poorly water soluble active ingredients and preparation thereof

Also Published As

Publication number Publication date
US12285521B2 (en) 2025-04-29
EP4631569A3 (en) 2025-12-24
IL266537A (en) 2019-07-31
US20230018732A1 (en) 2023-01-19
EP4631569A2 (en) 2025-10-15
NZ752556A (en) 2025-03-28
RU2019115816A (ru) 2020-12-17
EP3541362A1 (en) 2019-09-25
KR20190105569A (ko) 2019-09-17
RU2767436C2 (ru) 2022-03-17
AU2017359973A1 (en) 2019-05-02
DK3541362T3 (da) 2026-02-09
EP3541362B1 (en) 2025-11-05
BR112019009775A2 (pt) 2019-08-06
JP2020500220A (ja) 2020-01-09
US20210283047A1 (en) 2021-09-16
JP2023002545A (ja) 2023-01-10
CA3040014A1 (en) 2018-05-24
AU2017359973B2 (en) 2023-02-16
KR102499414B1 (ko) 2023-02-13
WO2018091473A1 (en) 2018-05-24
MX2019005160A (es) 2019-10-15
RU2019115816A3 (https=) 2021-03-15
MX389336B (es) 2025-03-20
US20200054550A1 (en) 2020-02-20
IL266537B1 (en) 2023-08-01
US20250281400A1 (en) 2025-09-11
CN110381921A (zh) 2019-10-25
FI3541362T3 (fi) 2026-02-05
PT3541362T (pt) 2026-02-06
US11007144B2 (en) 2021-05-18
IL266537B2 (en) 2023-12-01

Similar Documents

Publication Publication Date Title
ES3060767T3 (en) Alginate film comprising a triptan
ECSP18087352A (es) Formulaciones de un inhibidor de lsd1
MX2021009673A (es) Moduladores de ror-gamma.
CL2017000156A1 (es) Procedimientos para el tratamiento de paramixovirus.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2015002546A1 (es) Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos
MX379530B (es) Compuestos agonistas del receptor muscarínico m4.
CL2017000742A1 (es) Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue
BR112018069789A2 (pt) medicamento obtido pela combinação do agonista de fxr e arb
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
CL2017000782A1 (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación del virus del dengue
PE20190338A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
CL2017000050A1 (es) Terapia de combinación para el cáncer
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
MX380252B (es) Crenezumab para usarse en el tratamiento de enfermedad de alzheimer.
GT201700194A (es) Formulación de combinación de tesofensina y betabloqueante
AR100365A1 (es) Composición acuosa que comprende ibuprofeno y paracetamol en combinación, proceso para fabricarla y dispositivo inyector para administrarla
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
MX2019001577A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
DOP2017000014A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
MX2017003469A (es) Inhibidores macrociclicos de cinasa rip2.
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
MX2017009514A (es) Moduladores de los receptores a3 de adenosina.